抗雄激素单一疗法在晚期前列腺癌治疗中的应用

Antiandrogen monotherapy in the management of advanced prostate cancer.

作者信息

Kaisary A V

机构信息

Department of Urology, Royal Free Hospital NHS Trust, London, UK.

出版信息

Eur Urol. 1997;31 Suppl 2:14-9; discussion 24-7. doi: 10.1159/000474543.

DOI:10.1159/000474543

PMID:9074906

Abstract

The utility of monotherapy with antiandrogens in prostate cancer is under investigation. Flutamide (Eulexin, Schering-Plough International) appears equally effective to castration in prolonging progression-free survival. Nilutamide (Anandron, Roussel) has been studied less widely, but may represent a valid treatment option in advanced prostate cancer. Preliminary results suggest that bicalutamide (Casodex, Zeneca Ltd) is as effective as castration in non-metastatic disease. Monotherapy with non-steroidal antiandrogens may offer successful palliative management of advanced prostate cancer with significant value in enhancing certain aspects of quality of life.

摘要

抗雄激素单一疗法在前列腺癌治疗中的效用正在研究中。氟他胺（Eulexin，先灵葆雅国际公司）在延长无进展生存期方面似乎与去势疗法同样有效。尼鲁米特（Anandron，罗素公司）的研究范围较小，但可能是晚期前列腺癌的一种有效治疗选择。初步结果表明，比卡鲁胺（Casodex，阿斯利康有限公司）在非转移性疾病中与去势疗法效果相当。非甾体类抗雄激素单一疗法可能为晚期前列腺癌提供成功的姑息治疗，在提高生活质量的某些方面具有重要价值。